Found 549959 clinical trials
Sort by:
Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment
Not Applicable
Recruiting
- Conditions
- Helicobacter Pylori
- Interventions
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 414
- Registration Number
- NCT07122024
- Locations
- 🇨🇳
The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
AI for Detection of Brain Aneurysm: Low-cost Opportunistic Screening
Not Applicable
Not yet recruiting
- Conditions
- Intracranial Aneurysm
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- Ziekenhuis Oost-Limburg
- Target Recruit Count
- 10000
- Registration Number
- NCT07123818
Multispectral Optoacoustic Imaging for the Detection of Inflammation and Damage of Peripheral Nerves in Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy
Not yet recruiting
- Conditions
- CIDP - Chronic Inflammatory Demyelinating PolyneuropathyGuillain-Barré Syndrome (GBS)
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 30
- Registration Number
- NCT07121985
Feasibility and Outcomes of 3D-printed External Cranial Orthosis After Craniectomy
Active, not recruiting
- Conditions
- Traumatic Brain InjuryAcquired Brain InjuryBrain TumorStroke
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- Tan Tock Seng Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT07122752
- Locations
- 🇸🇬
Tan Tock Seng Hospital, Singapore, Singapore
Preliminary Clinical Study on the Effect of Bacillus Subtilis on the Efficacy of Infliximab in Patients With Crohn's Disease
Not Applicable
Recruiting
- Conditions
- Mild to Severe Crohns Disease
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-14
- Target Recruit Count
- 24
- Registration Number
- NCT07123207
- Locations
- 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Not Applicable
Not yet recruiting
- Conditions
- Relapsed and Refractory DLBCL
- Interventions
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT07122609
- Locations
- 🇨🇳
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
A Five-Day Contagious Laughter Intervention for Adult Well-being
Not Applicable
Completed
- Conditions
- Well-being
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- Zayed University
- Target Recruit Count
- 100
- Registration Number
- NCT07123571
- Locations
- 🇦🇪
Zayed University, Abu Dhabi, United Arab Emirates
Study of Acquired Resistance to Alkylator Chemotherapy in Endocrine Neoplasms
Recruiting
- Conditions
- Neuroendocrine (NE) TumorsEndocrine Cancer
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- Uppsala University
- Target Recruit Count
- 94
- Registration Number
- NCT07121998
- Locations
- 🇸🇪
Akademiska Sjukhuset, Uppsala, Sweden
Engineered T-Cell Therapy for Patients With ALPP-Positive Advanced Solid Tumors
Not Applicable
Not yet recruiting
- Conditions
- Recurrent or Metastatic Solid Tumors With Positive ALPP
- Interventions
- Biological: Anti ALPP CAR-T cells treatment
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- Haifeng Qin
- Target Recruit Count
- 24
- Registration Number
- NCT07123493
- Locations
- 🇨🇳
Beijing GoBroad Hospital, Beijing, Beijing, China
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States
Not Applicable
Not yet recruiting
- Conditions
- Neuromuscular AgentsPeripheral Nervous System AgentsPhysiological Effects of DrugsAcetylcholine Release InhibitorsMembrane Transport ModulatorsMolecular Mechanisms of Pharmacological ActionCholinergic AgentsNeurotransmitter AgentsincobotulinumtoxinABotulinum Toxins, Type A
- Interventions
- Drug: NT 201 Placebo
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- Merz North America, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT07122193